Business Context and Reporting Period
This Form 8-K filing by Cocrystal Pharma, Inc. reports corporate governance changes effective March 11, 2015. The filing addresses the departure of the Chief Executive Officer and the appointment of an interim successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- CEO Departure: Dr. Gary Wilcox stepped down as Chief Executive Officer due to medical reasons and ceased serving as Co-Chairman of the Board.
- Interim CEO Appointment: Mr. Jeffrey Meckler was appointed Interim Chief Executive Officer, effective with the filing of the Company's Form 10-K in late March 2015.
- Board Restructuring: Dr. Wilcox was appointed Vice Chairman and will remain a director and senior advisor. Dr. Raymond F. Schinazi was appointed Chairman of the Board.
Guidance, Outlook, and Compensation
The filing details the compensatory arrangement for the new Interim CEO, Mr. Meckler, under an employment agreement dated March 13, 2015, and amended March 17, 2015:
- Salary: $20,000 per month, in addition to director compensation.
- Equity Grant: An option to purchase up to 1,750,000 shares of common stock, effective March 23, 2015, vesting in six approximately equal monthly installments starting one month after the grant date.
- Bonus: Eligibility for a discretionary bonus of up to $100,000 based on performance criteria established by the Board.
- Term: The agreement has an initial term of six months, subject to renewal.
The filing does not provide specific financial guidance, outlook, or discussion of risks beyond the context of the leadership transition.
Investor Verification Checklist
- Verify the exact effective date of the Form 10-K filing to confirm the start date of Mr. Meckler's tenure as Interim CEO.
- Review the specific performance criteria for the $100,000 discretionary bonus once established by the Board.
- Monitor the vesting schedule of the 1,750,000 share option grant for potential dilution impacts.
- Confirm the status of Dr. Wilcox's medical leave and his ongoing role as a senior advisor.